Venetoclax + ASTX727 for Acute Myeloid Leukemia

This trial tests two different durations of treatment for individuals newly diagnosed with acute myeloid leukemia (AML), a type of blood cancer. Participants will receive a combination of two drugs, Decitabine and Cedazuridine (ASTX727), along with venetoclax, which work together to kill cancer cells. The trial compares the standard length of venetoclax treatment to a shorter one to determine if both are equally effective. It seeks participants with untreated AML who can handle oral medication, excluding those with certain genetic mutations or those already treated for AML. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial does not specify if you need to stop taking your current medications, but it does mention that you cannot receive other investigational agents while on the trial. It's best to discuss your current medications with the trial team to get specific guidance.

Research has shown that the combination of decitabine and cedazuridine (ASTX727) with venetoclax has been tested for safety in treating patients with acute myeloid leukemia (AML). In previous studies, many patients experienced side effects. Specifically, serious side effects occurred in about 84% of patients, with most experiencing some form of adverse reaction. Common issues included infections and fever due to low white blood cell counts.

Despite these risks, the treatment can be beneficial. It proved effective in about 42% of cases, where the cancer became undetectable. This indicates that while risks exist, many patients respond well to the treatment.

Most treatments for Acute Myeloid Leukemia (AML) involve chemotherapy or a bone marrow transplant, which can be harsh and have significant side effects. Researchers are excited about the combination of Decitabine and Cedazuridine (ASTX727) with Venetoclax because it offers a potentially more targeted approach. Venetoclax works by inhibiting a protein called BCL-2, which helps cancer cells survive, thereby promoting their death. What makes this treatment unique is its dual approach: one arm uses Venetoclax for a standard duration, while the other explores a shorter duration, potentially reducing side effects and improving patient tolerance. This novel approach could offer a more effective and manageable treatment option for AML patients.

Research has shown that a treatment combining decitabine and cedazuridine (ASTX727) with venetoclax can effectively treat acute myeloid leukemia (AML). In studies, 41.6% to 46.5% of patients achieved a complete response, indicating significant improvements in their condition. This trial will evaluate two treatment arms: one where participants receive ASTX727 with standard-duration venetoclax, and another with a shorter duration of venetoclax. Venetoclax works by blocking a protein essential for cancer cell survival, potentially stopping their growth. Patients receiving this combination lived an average of about 13.5 months, suggesting potential benefits for those newly diagnosed with AML.¹³⁴⁵⁶